GlaxoSmithKline | GSK - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
AbbVie USD 3.58B 316M 2026-03
Alcon AG USD 882M 19M 2026-03
Amgen USD 1.58B 354M 2026-03
argenx SE USD 417M 62M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Bayer EUR 3.7B 356M 2026-03
Biogen USD 709.7M 155.4M 2026-06
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Fresenius EUR 819M 143M 2025-12
Fresenius Medical Care EUR 749M 36M 2026-03
Genmab DKK 208M 60M 2025-12
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.19B 75M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
GRIFOLS EUR 281M 5.7M 2026-03
Hikma Pharmaceutical USD 288M 149M 2025-12
Lakefront Biotherapeutics EUR 35.5M 8.91M 2026-03
Merck EUR 1.52B 80M 2026-03
Merck USD 2.67B 180M 2026-03
Novartis USD 3.24B 101M 2026-06
Novo Nordisk DKK 13.22B 4.22B 2026-03
Orion EUR 98.9M 7M 2026-06
Pfizer USD 2.92B 1.16B 2026-03
Philips EUR 1.21B 23M 2026-06
Recordati EUR 192.76M 5.52M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.33B 419M 2026-03
Smith & Nephew USD 1.42B 65M 2025-12
UCB EUR 1.47B 193M 2025-12